Navigation Links
R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia
Date:1/24/2011

the leadership of Yukihiko Mashima, CEO and a medical doctor, the company is developing new drugs on the theme "Physician-Oriented New Drug Innovation," targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent. We aim at becoming a "global pharmaceutical company specializing in specific fields (ophthalmology and dermatology) and developing pharmaceutical products through the eyes of doctors and selling." We are promoting development of new drugs of unmet medical needs (medical needs that are not fulfilled yet) which the government recommends and assists, orphan drugs and the drugs in the field of anti-aging (lifestyle drugs).Contact:Koji NakamuraBusiness Management Department;TEL: +81-3-3596-8011e-mail: koji.nakamura@rtueno.co.jp URL: http://rtechueno.com/en/index.html
'/>"/>
SOURCE R-Tech Ueno, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
2. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
3. R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 BGI announced today ... Hong Kong has been accredited by the ... is the first clinical next-generation-sequencing laboratory to receive the ... the highest standard in clinical laboratory practices. Complementary to the ... laboratory process, and multiple ISO certifications, the CAP certification ...
(Date:7/2/2015)... 2015   Wilson Therapeutics AB , a privately-held ... to its board of directors. The appointment was approved ... June 30. "We are delighted to welcome ... Hansson , CEO of Wilson Therapeutics. "Hans brings significant ... forward to his contributions to the Company." ...
(Date:7/1/2015)... 1, 2015 The Coalition of State ... and regional professional rheumatology societies, today released the ... explored perceptions of biosimilars and the potential impact ... Biosimilars are medicines that are highly similar, ... notably different from generic medications in that it ...
Breaking Medicine Technology:BGI Receives Accreditation from the College of American Pathologists (CAP) 2Wilson Therapeutics Appoints Hans Schikan to its Board of Directors 2Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2
... April 27 SI-BONE, Inc. ( Cupertino, California ), ... minimally invasive surgical (MIS) device to treat the sacroiliac (SI) joint ... at upcoming 2010 minimally invasive spine surgery meetings. , ... SI-BONE has been working with ...
... CareFusion Corporation (NYSE: CFN ) today announced plans to release third ... close of trading on the New York Stock Exchange. , ... The company will host a webcast and conference call on May 6 ... to discuss the results for its third quarter, ended on March 31, 2010 ...
Cached Medicine Technology:iFuse Implant System(TM) to be Presented at Leading Minimally Invasive Spine Surgical Meetings 2iFuse Implant System(TM) to be Presented at Leading Minimally Invasive Spine Surgical Meetings 3iFuse Implant System(TM) to be Presented at Leading Minimally Invasive Spine Surgical Meetings 4CareFusion Will Host an Earnings Conference Call on May 6 to Discuss the Results for the Third Quarter of Fiscal 2010 2
(Date:7/2/2015)... ... July 02, 2015 , ... Scientists at ... nearly $4 million through five federal grants to study a group of related ... deadly diseases. , The research will be conducted in the Regional Biocontainment ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... healthcare providers, has been retained to lead a national chief operating officer ... executive search firms in the healthcare industry, B. E. Smith has recently placed ...
(Date:7/2/2015)... ... July 02, 2015 , ... Evolved Ayurvedic Discoveries , ... an intention to partner with companies that share a similar mission of providing ... water soluble, Cannabidiol (CBD) formulations, combined with Ayurvedic herbs, are now available for ...
(Date:7/2/2015)... ... ... A team of quality control (QC) experts at GE Healthcare, led by ... enhanced workflow. Now, Dr. Dunne’s lab has set a lofty goal: to become the ... network. , Join the team members for a new, free educational webinar ...
(Date:7/2/2015)... ... July 02, 2015 , ... Cs &A, the ... Timing announced the release and publication of their newest offering to complement the ... and Newsletter. , Designed in support of coverage for the full spectrum ...
Breaking Medicine News(10 mins):Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 4Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3Health News:GE Healthcare Webinar Spotlights GE’s Own, Internal QC Lab Enhancements with Six Sigma 2Health News:GE Healthcare Webinar Spotlights GE’s Own, Internal QC Lab Enhancements with Six Sigma 3Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 2Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 3Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 4
... in blood pressure, disease scores , , SUNDAY, March 30 ... electronically, good doctor-patient communication helps reduce the risk of ... study. , The four-year study included rural and urban ... were otherwise healthy. They were divided into two groups, ...
... agent that combines 2 medications , , SUNDAY, March 30 (HealthDay ... to make sense of a trial showing that a drug ... no apparent benefit to people at high risk of heart ... a well-known statin -- simvastatin -- with ezetimibe, which also ...
... In a comparison of anticoagulants and stents for use ... and tirofiban had similar outcomes for some cardiac measures ... received stents that released the drug sirolimus had a ... months than patients who received uncoated stents, according to ...
... restenosis risk and don,t increase mortality probability , , SUNDAY, ... tubing placed in diseased coronary arteries to keep them ... attack patients, new research shows. , In the largest ... -- the drug in question retards the growth of ...
... RN ... Organization, HOUSTON, March 29 ... a stronger voice to speak,out for patients and themselves, a northwest Houston ... bargaining,rights., RNs at Cypress Fairbanks Medical Center Hospital voted 119 to ...
... cancer deaths could be avoided with lifestyle changes, experts ... therapies that could cut cancer deaths in half. , ... recent American Cancer Society report that said as many ... with lifestyle changes, such as quitting smoking, maintaining a ...
Cached Medicine News:Health News:Combining Internet With Office Visits Cut Heart Attack Risks 2Health News:Cholesterol Drug Controversy Continues 2Health News:Cholesterol Drug Controversy Continues 3Health News:Comparison of anticoagulants for angioplasty show similar outcomes 2Health News:Drug-Eluting Stents Safe After Heart Attack 2Health News:First Unionized Hospital in Texas 2Health News:First Unionized Hospital in Texas 3Health News:You May Be the Key to Cancer Prevention 2Health News:You May Be the Key to Cancer Prevention 3
Alvis foreign body spud 4 3/4 inches, oval curette 1 x 3 mm with fine point....
... from MMA/VP material and has a high water ... with the base curve and total diameter as ... in a power range of -30.00DS to +30.00DS,Simplon ... and therapeutic applications including the controlled on-eye delivery ...
... Focus Night & Day soft contact lenses ... protect the cornea and to relieve corneal ... chronic ocular pathologies such as bullous keratopathy, ... dystrophies as well as post-surgical conditions resulting ...
Cottle-Joseph Double Hook 12 mm wide....
Medicine Products: